The pivotal phase 3 trial REACH-2 evaluated ramucirumab versus placebo in patients with advanced HCC (with disease progression on or intolerance to sorafenib) and elevated baseline AFP levels (≥400 ng/mL) [28]. Here, AFP is linked to hepatocellular carcinoma.